Drug intelligence / Profile preview

YHR-1705

Development stage: Unknown
Lead developer: Yuhan
Modality: Small Molecules
Administration: Oral

Overview

YHR-1705 is a small molecule drug initially developed by Yuhan Corp. It is under investigation primarily in the therapeutic area of endocrinology and metabolic diseases. The drug has been studied for potential indications including type 2 diabetes mellitus and dyslipidemias. A phase 1 clinical trial was conducted to investigate the pharmacokinetic drug interaction between YHR-1705 and another compound named YHR-1706 in healthy volunteers. The development status remains pending with no approval yet reported.

Other names: YHR-1705YHR1705YHR 1705

Beyond the preview

Go deeper on YHR-1705.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YHR-1705.

Explore the full profile